
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
Details : TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX und...
Product Name : Tpoxx
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
